Premium
The association between MIF‐173 G>C polymorphism and prostate cancer in southern Chinese
Author(s) -
Ding G.X.,
Zhou S.Q.,
Xu Z.,
Feng N.H.,
Song N.H.,
Wang X.J.,
Yang J.,
Zhang W.,
Wu H.F.,
Hua L.X.
Publication year - 2009
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.21304
Subject(s) - medicine , prostate cancer , oncology , polymorphism (computer science) , gynecology , genetics , genotype , cancer , gene , biology
Abstract Background and Objectives Accumulating epidemiological and molecular evidence suggests that inflammation is an important component in the etiology of PCa. Macrophage migration inhibitory factor (MIF) plays an important role in the pro‐ and anti‐inflammatory response to infection. This study is aimed at investigating the potential association between MIF‐173 G>C polymorphism, Gleason score, clinical stage, and prostate‐specific antigen (PSA) value with respect to PCa incidence among the Han nationality in Southern China. Methods Genotyping was performed by using tetraprimer polymerase chain reaction (PCR) on 259 PCa patients and 301 cancer‐free controls. Results We found that the MIF‐173*C variant allele was significantly associated with an increased risk of PCa [adjusted odd ratio (OR) = 2.99, 95% confident interval (CI): 1.94–4.60] and higher Gleason scores from the PCa subjects (adjusted OR = 10.72, 95% CI: 5.35–21.49). In addition, we noted that the MIF −173*C variant allele was related to higher clinical stages and PSA values in PCa patients (adjusted OR = 15.68, 95% CI: 7.40–33.23; adjusted OR = 4.37, 95% CI: 2.41–7.92, respectively). Conclusion Our data suggest that MIF‐173 polymorphisms may be associated with a higher incidence of prostate cancer compared to controls, and appears to be associated with higher Gleason scores, higher clinical stages, and PSA values in those with prostate cancer. J. Surg. Oncol. 2009;100:106–110. © 2009 Wiley‐Liss, Inc.